| Bioactivity | Orenetide is an innovative peptide drug developed in the study to restore sexual desire and concomitant functions in women with HSDD (Hypoactive desire disorder)[1] |
| Target | an innovative peptide drug developed in Russia to restore sexual desire and concomitant functions in women with HSDD（Hypoactive desire disorder）；https://cardiosomatics.orscience.ru/0300-9092/article/view/249549；?NIH药物肽，袁子琛要求上线，2023/11/4 |
| Name | Orenetide |
| CAS | 1124168-43-9 |
| Sequence | Thr-Lys-Pro-Arg-Pro |
| Shortening | TKPRP |
| Formula | C26H47N9O7 |
| Molar Mass | 597.71 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sukhikh G.T., et al. Orenetide for the treatment of hypoactive sexual desire disorder: results of a randomized placebo-controlled trial. Obstetrics and Gynegology. 2022 |
Orenetide
CAS: 1124168-43-9 F: C26H47N9O7 W: 597.71
Orenetide is an innovative peptide drug developed in the study to restore sexual desire and concomitant functions in wom
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.